US Stem Cell's total inventories for the quarter that ended in Dec. 2022 was $0.00 Mil. US Stem Cell's average total inventories from the quarter that ended in Sep. 2022 to the quarter that ended in Dec. 2022 was $0.00 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. US Stem Cell's Net-Net Working Capital per share for the quarter that ended in Dec. 2022 was $-0.02.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
US Stem Cell's Days Inventory for the
three
months ended in Dec. 2022 was 18.25.
Inventory Turnover measures how fast the company turns over its inventory within a year.
US Stem Cell's Inventory Turnover for the quarter that ended in Dec. 2022 was 5.00.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
US Stem Cell's Inventory-to-Revenue for the quarter that ended in Dec. 2022 was 0.05.
US Stem Cell (OTCPK:USRM) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
US Stem Cell's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2022 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
US Stem Cell's Inventory to Revenue for the quarter that ended in Dec. 2022 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
US Stem Cell Total Inventories Related Terms
US Stem Cell Total Inventories Historical Data
* Premium members only.
The historical data trend for US Stem Cell's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
US Stem Cell (USRM) has a Total Inventories of $0.00 Mil as of Dec. 2022. The total amount of inventory as recorded on a company's balance sheet. View historical data for US Stem Cell and its competitors.
Is US Stem Cell's Total Inventories too high?
US Stem Cell's current Total Inventories is $0.00 Mil. Overall, US Stem Cell has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does US Stem Cell's Total Inventories compare to NOVNQ and RGRX?
US Stem Cell's Total Inventories of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for US Stem Cell and its competitors. US Stem Cell's current Total Inventories is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is US Stem Cell stock overvalued right now?
US Stem Cell (USRM) has a current Total Inventories of $0.00 Mil. The current Total Inventories is $0.00 Mil. US Stem Cell's overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For US Stem Cell (USRM), the current Total Inventories is $0.00 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
US Stem Cell Inc is a biotechnology company engaged in the discovery and development of autologous cell therapies for the treatment of chronic and acute heart damage. Its product includes MyoCell, a clinical therapy designed to populate regions of scar tissue within a patient's heart with autologous muscle cells, or cells from a patient's body, for the purpose of improving cardiac function in chronic heart failure patients. The company's discoveries include multiple cell therapies in various stages of development that repair damaged tissues throughout the body due to injury or disease so that patients may return to a normal lifestyle.
12GF Score
Get the complete analysis for USRM
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
USRM has been successfully added to your 
